Acitretin

Noelani E Gonzalez Ortiz, Rajiv I. Nijhawan, Jeffrey M. Weinberg

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Acitretin, a synthetic retinoid, is the pharmacologically active metabolite of etretinate. It is currently approved by the US Food and Drug Administration for the treatment of severe psoriasis in adults and has been established as a second-line therapy for the treatment of psoriasis resistant to the use of topical therapy. It is also an option for generalized pustular psoriasis, palmoplantar pustulosis, exfoliative erythrodermic psoriasis, and severe psoriasis in the setting of acitretin. It also has been shown to have chemo-preventative characteristics. Acitretin is limited by its teratogenicity and therefore considered inappropriate in most female patients of childbearing age. Common side effects include mucocutaneous dryness and elevated triglycerides.

Original languageEnglish (US)
Pages (from-to)390-399
Number of pages10
JournalDermatologic Therapy
Volume26
Issue number5
DOIs
StatePublished - Sep 1 2013

Keywords

  • acitretin
  • mucocutaneous
  • psoriasis
  • retinoid
  • teratogenicity

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Acitretin'. Together they form a unique fingerprint.

  • Cite this

    Ortiz, N. E. G., Nijhawan, R. I., & Weinberg, J. M. (2013). Acitretin. Dermatologic Therapy, 26(5), 390-399. https://doi.org/10.1111/dth.12086